title: Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.
abstract: Analysis of the specificity of bactericidal antibodies in normal, convalescent, and postvaccination human sera is important in understanding human immunity to meningococcal infections and can aid in the design of an effective group B vaccine. A collection of human sera, including group C and group B convalescent-phase sera, normal sera with naturally occurring cross-reactive bactericidal activity, and some postvaccination sera, was analyzed to determine the specificity of cross-reactive bactericidal antibodies. Analysis of human sera using a bactericidal antibody depletion assay demonstrated that a significant portion of the bactericidal activity could be removed by purified lipopolysaccharide (LPS). LPS homologous to that expressed on the bactericidal test strain was most effective, but partial depletion by heterologous LPS suggested the presence of antibodies with various degrees of cross-reactivity. Binding of anti-L3,7 LPS bactericidal antibodies was affected by modification of the core structure, suggesting that these functional antibodies recognized epitopes consisting of both core structures and lacto-N-neotetraose (LNnT). When the target strain was grown with 5'-cytidinemonophospho-N-acetylneuraminic acid (CMP-NANA) to increase LPS sialylation, convalescent-phase serum bactericidal titers were decreased by only 2- to 4-fold, and most remaining bactericidal activity was still depleted by LPS. Highly sialylated LPS was ineffective in depleting bactericidal antibodies. We conclude that natural infections caused by strains expressing L3,7 LPS induce persistent, protective bactericidal antibodies and appear to be directed against nonsialylated bacterial epitopes. Additionally, subsets of these bactericidal antibodies are cross-reactive, binding to several different LPS immunotypes, which is a useful characteristic for an effective group B meningococcal vaccine antigen.
authors.affiliation: Division of Bacterial and Rickettsial Diseases, Walter Reed Army Institute of Research, Silver Spring, MD 20910-7500, USA. deb.schmiel1@us.army.mil
authors.forename: Deborah H
authors.initials: DH
authors.lastname: Schmiel
authors.forename: Elizabeth E
authors.initials: EE
authors.lastname: Moran
authors.forename: Paul B
authors.initials: PB
authors.lastname: Keiser
authors.forename: Brenda L
authors.initials: BL
authors.lastname: Brandt
authors.forename: Wendell D
authors.initials: WD
authors.lastname: Zollinger
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D001770:Blood Bactericidal Activity / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003429:Cross Reactions; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D008070:Lipopolysaccharides / Q000276:immunology*; D008589:Meningococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D008070:Lipopolysaccharides; D022401:Meningococcal Vaccines